Grassley Seeks Marketing and Safety Documents from Major Drug Maker
WASHINGTON — Sen. Chuck Grassley is asking the drug maker, Eli Lilly and Company, for information related to the risks and marketing of the anti-psychotic drug Zyprexa. Grassley made this request in response to allegations that the company downplayed safety risks and engaged in other improper marketing practices that may be jeopardizing patients’ health.
The text of Grassley’s letter can be found in the printer-friendly version of this news release.
Next Article Previous Article
- Wyden Hearing Statement at Finance Committee Hearing on Pharmacy Benefit Managers and the Prescription Drug Supply Chain
- Wyden Investigation Finds Credit Suisse Complicit in Ongoing Tax Evasion by Ultra-Wealthy Americans
- Senate Finance Committee Chair Wyden Expands Investigation of Auto Supply Chain Links to Forced Labor in Xinjiang, China
- Wyden Announces Finance Committee Hearing on Pharmacy Benefit Managers and the Prescription Drug Supply Chain
- Wyden Hearing Statement at Finance Committee Hearing on the President’s Trade Agenda